From 1 January 2021, a prescription issued in an
EEA member state (EU countries, Iceland, Liechtenstein and Norway) or Switzerland can be dispensed in the UK if the prescriber is from a profession recognised by this guidance that is legally entitled to issue a prescription of that kind in the country in which the prescription is issued.
Actions for pharmacists
EEA or Swiss prescription, you should:
identify the prescriber in the same way that you do now. The name, professional qualifications and contact details of the prescriber (including work address, email address and telephone or fax number with the appropriate international prefix) should be clearly stated on the prescription along with the name of the country in which the prescription was issued
Apply for a licence to market a medicine in the UK
How to license a medicine for sale in the UK, including applications through national and international routes.
From: Contents
Print this page
This guidance also covers licensing a medicine in Northern Ireland through the centralised, decentralised and mutual recognition European procedures.
Which procedure to follow
There are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotland and Wales) or Northern Ireland. The options available will be determined by the intended market and the type of application. The markets in which each route is applicable are indicated in the following guidance:
UK confirms authorization of second COVID-19 vaccine vanguardngr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vanguardngr.com Daily Mail and Mail on Sunday newspapers.
The UK has pre-ordered 100 million doses of the vaccine
The NHS will prioritise giving the first dose of the vaccine to those most in need following advice from the Joint Committee on Vaccination and Immunisation (
JCVI) and the UK’s Chief Medical Officers
The second COVID-19 vaccine has been authorised for use in the UK, allowing a significant expansion of the immunisation programme with hundreds more vaccination sites opening in the coming weeks and months to protect those most at risk from the virus.
The UK regulator has accepted the recommendation of the Commission on Human Medicines and authorised the Oxford University/AstraZeneca COVID-19 vaccine. This follows months of rigorous clinical trials involving tens of thousands of people and an extensive analysis of the vaccine’s safety, quality and effectiveness by the Medicines and Healthcare products Regulatory Agency (